Pharmicell and the University of Utah present their research findings on the fusion of stem cells and gene in an international journal
Co-headed by Kim, Hyeon-Soo and Kim, Seong-Rae, Pharmicell(005690)’s bone marrow-derived mesenchymal stem cells loaded with a newly-developed polymer will serve as an important medium for gene therapy.
Research results that therapeutic gene delivery using ‘PAM-ABP’(bio-reducible polymer) into human mesenchymal stem cells leads to positive gene expression is published in the ‘Journal of Controlled Release(JCR)’ under the title of ‘VEGF therapeutic gene delivery using dendrimer type bio-reducible polymer into human mesenchymal stem cells (hMSCs)’.
JCR (Impact Factor: 7.768 in 5 years) is world renowned for drug delivery as the top 10 percent of the journals in pharmacy/pharmacology.
‘PAM-ABP’ is a newly developed polymer substance to prevent issues such as mutation, immunogenicity, and cytotoxicity brought by viral vector which is generally used for gene delivery.
The research found that ‘PAM-ABP’ effectively promotes gene delivery into hMSCs and that optimizes gene expression, prevents cytotoxicity and helps keep stem cells’ original characteristics. This implies a high possibility of succeeding in developing stem cell-based gene therapy.
“Despite the fact that stem cells have been developing as the next generation biopharmaceuticals, targeting and gene delivery that promotes survival rate and therapy efficiency are required at the clinical trials to ensure the effectiveness. Inosculating MSCs with a newly-developed polymer and relevant genes will allow the development of the next generation stem cell-gene cures,” said Dr. Kim Sung Wan at the University of Utah, co-researcher of the study.,
After Pharmicell signed an MOU with the University of Utah in 2012 to jointly develop an improved delivery system to send stem cell cures to affected area of a patient, their findings have been receiving a great attention worldwide.
In the first half of this year, the research team published study results on the development of drug delivery system to increase stem cell’s survival and in vivo engraftment rates by inosculating MSCs with the micro-unit PPP(Porous PLGA/PEI1.8k,) in the same journal.
“We are now speeding up our efforts to develop next generation stem cell therapy loaded with gene of dendritic cell. Developing stem cell-based biopharmaceuticals is underway worldwide and our company will make our way to create a new market in this field,” said Kim, Hyeon-Soo, Pharmicell CEO.